Related Experiment Video
Updated: May 17, 2026
09:03
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
[Antiangiogenic agents: current limits in thoracic oncology]
Eric Dansin1, Géraldine Lauridant, Bachar Chahine
1CLCC Oscar-Lambret, département de cancérologie générale, Lille Cedex, France. e-dansin@o-lambret.fr
Bulletin Du Cancer
|November 2, 2012
Summary
Antiangiogenic agents show promise in various cancers but have limited use in thoracic oncology. Further research is needed to overcome challenges in efficacy, biomarkers, and cost-effectiveness for broader application.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Context:
- Antiangiogenic agents are established treatments for renal, colorectal, and breast cancers.
- Their application in thoracic oncology remains limited, with bevacizumab being a notable exception.
Purpose:
- To review the current limitations of antiangiogenic agents in thoracic oncology.
- To discuss challenges related to efficacy, activity, tolerance, and therapeutic strategies.
- To address issues concerning predictive biomarkers and cost-effectiveness.
Summary:
- This review examines the restricted role of antiangiogenic agents in thoracic oncology, contrasting with their success in other cancer types.
- Key limitations discussed include efficacy, patient tolerance, and suboptimal therapeutic strategies.
- The review also highlights the need for predictive biomarkers and improved cost-effectiveness.
Impact:
- The findings aim to guide future research and clinical strategies for enhancing antiangiogenic therapy in thoracic malignancies.
- Addressing these limitations could expand treatment options and improve outcomes for patients with thoracic cancers.
- This review provides a critical overview for oncologists and researchers in the field.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...